Premium
Hemodynamic effects of quinidine and famotidine in patients with congestive heart failure
Author(s) -
Kirch Wilhelm,
Halabi Atef,
Hinrichsen Holger
Publication year - 1992
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1038/clpt.1992.29
Subject(s) - impedance cardiography , quinidine , medicine , stroke volume , famotidine , cardiology , heart failure , heart rate , blood pressure , hemodynamics , cardiac output , ejection fraction , anesthesia , placebo , alternative medicine , pathology
In a randomized, placebo‐controlled, double‐blind study, 12 patients with congestive heart failure (New York Heart Association class II) were successively treated for 1 week each with placebo, 40 mg famotidine, and 1000 mg quinidine. On the seventh treatment day, heart rate, blood pressure, systolic time intervals, impedance cardiography, and Doppler ultrasound were measured. Heart rate and blood pressure were not markedly altered by either drug. By contrast, quinidine and famotidine significantly decreased stroke volume and cardiac output in impedance cardiography and Doppler ultrasound ( p < 0.05). A high correlation between both noninvasive methods was found for cardiac output and stroke volume ( r = 0.93 and r = 0.97 for stroke volume 1½ hours after quinidine and placebo administration, respectively). In addition, the mechanocardiographic ratio of the preelection period to the left ventricular ejection time in systolic time intervals increased significantly 1½ and 3 hours after administration of quinidine and famotidine ( p < 0.05). In conclusion, both quinidine and famotidine exert similar negative effects on cardiac performance, with no significant differences in hemodynamic parameters emerging between the antiarrhythmic agent and the H 2 ‐receptor antagonist. Clinical Pharmacology and Therapeutics (1992) 51, 325–333; doi: 10.1038/clpt.1992.29